Skip to main content

. 1997 Feb;62(2):200–201. doi: 10.1136/jnnp.62.2.200-b

Multiple sclerosis: longitudinal measurement of interleukin-1 receptor antagonist.

R Voltz, M Hartmann, S Spuler, A Scheller, N Mai, R Hohlfeld, T Yousry

PMCID: PMC486741 PMID: 9048730

200

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Arend W. P. Interleukin-1 receptor antagonist. Adv Immunol. 1993;54:167–227. doi: 10.1016/s0065-2776(08)60535-0. [DOI] [PubMed] [Google Scholar]
Fisher C. J., Jr, Dhainaut J. F., Opal S. M., Pribble J. P., Balk R. A., Slotman G. J., Iberti T. J., Rackow E. C., Shapiro M. J., Greenman R. L. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA. 1994 Jun 15;271(23):1836–1843. [PubMed] [Google Scholar]
Gruss H. J., Dölken G., Brach M. A., Mertelsmann R., Herrmann F. High concentrations of the interleukin-1 receptor antagonist in serum of patients with Hodgkin's disease. Lancet. 1992 Oct 17;340(8825):968–968. doi: 10.1016/0140-6736(92)92849-b. [DOI] [PubMed] [Google Scholar]
Olsson T. Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev. 1995 Apr;144:245–268. doi: 10.1111/j.1600-065x.1995.tb00072.x. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES